Cargando…
No Evidence of Pritelivir Resistance Among Herpes Simplex Virus Type 2 Isolates After 4 Weeks of Daily Therapy
Background. Pritelivir is a novel helicase-primase inhibitor in clinical development for treatment of herpes simplex virus type 2 (HSV-2) infections. In preclinical work, resistance-mediating mutations were identified in the HSV-2 genome at 3 loci in the UL5 gene and 1 locus in UL52. Methods. To eva...
Autores principales: | Edlefsen, Paul T., Birkmann, Alexander, Huang, Meei-Li, Magaret, Craig A., Kee, Jia Jin, Diem, Kurt, Goldner, Thomas, Timmler, Burkhard, Stoelben, Susanne, Ruebsamen-Schaeff, Helga, Zimmermann, Holger, Warren, Terri, Wald, Anna, Corey, Lawrence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918824/ https://www.ncbi.nlm.nih.gov/pubmed/27056950 http://dx.doi.org/10.1093/infdis/jiw129 |
Ejemplares similares
-
Discovery,
Chemistry, and Preclinical Development
of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes
Simplex Virus Infections
por: Birkmann, Alexander, et al.
Publicado: (2022) -
1060. Pritelivir in Immunocompromised Patients with Mucocutaneous Acyclovir-Resistant Herpes Simplex Virus-Infections – First Case Series
por: Albrecht, Kim WorkowskiJoerg, et al.
Publicado: (2021) -
Therapeutic Vaccine for Genital Herpes Simplex Virus-2 Infection: Findings From a Randomized Trial
por: Bernstein, David I., et al.
Publicado: (2017) -
Invasive Obstetric Procedures and Cesarean Sections in Women With Known Herpes Simplex Virus Status During Pregnancy
por: Stankiewicz Karita, Helen C, et al.
Publicado: (2017) -
Genital Herpes Simplex Virus Type 2 Suppression With Valacyclovir Is Not Associated With Changes in Nugent Score or Absolute Abundance of Key Vaginal Bacteria
por: Babu, Tara M, et al.
Publicado: (2023)